TX-COGNITE
9.1.2023 15:36:39 CET | Business Wire | Press release
Cognite, a global leader in industrial software, today announced four appointments to lead the company’s scaling efforts for its next stage of growth. Cognite's new executive leaders are Moe Tanabian, Chief Product Officer (CPO); Paul Lightfoot, SVP of User Experience; Emmanuelle Camus, President of Cognite EMEA; and Liat Berger, Chief Human Resources Officer (CHRO). These leaders held roles of increasing responsibility at Red Hat, Microsoft, Amazon, PTC, and Aker Solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230109005470/en/
L-R Liat Berger, CHRO; Moe Tanabian, CPO; Emmanuelle Camus, President EMEA; Paul Lightfoot, SVP UX (Photo: Business Wire)
Cognite’s CEO Girish Rishi said, "Building a high-performance team and developing our talent is a top priority. I'm pleased to welcome these leaders with diverse, global experiences, including deep technical skill sets and tenures at Fortune 500 companies. These accomplished executives will help us further scale our commitments to customers and partners as we solve the industrial data availability-to-value problem together."
Moe Tanabian, Cognite’s new Chief Product Officer, is charged with product strategy and execution, as well as product management, design, and engineering. He has been driving innovation at scale for nearly three decades, particularly in the areas of software products, AI, ML, and IoT. Tanabian recently served as Vice President and General Manager of Azure Light Edge for Microsoft, driving more than $2 billion P&L for Microsoft's portfolio of products in IoT, OT, and embedded industrial domains. Prior to his role at Microsoft, Tanabian worked for Samsung as Vice President of Smart Products and IoT, as well as Amazon, where he led the efforts to build and deliver the Amazon Android Appstore on Kindle Fire and Amazon Phone devices. Tanabian holds a master’s degree in Systems and Computer Engineering from Carleton University, Ottawa, Ontario and an MBA from the School of Business Queen’s University, Kingston, Ontario.
Liat Berger will serve as the new CHRO. She has a demonstrated track record of HR leadership with global multi-site companies and will help drive Cognite’s scale-up strategy. She has spent the last ten years at Aker Solutions and most recently served as Senior Vice President of People and Organization, Corporate, where she focused on business strategy by helping leaders identify, prioritize and build organizational capabilities, behaviors, and structures needed to support the change agenda. She also served as the Head of P&O for the Subsea Organization at Aker Solutions, which was composed of 4,500 employees distributed in 10 different locations on four different continents. Her expertise is building and balancing global companies while incorporating local realities, and she will play a key role in energizing Cognite’s global workforce. She is a graduate in Business Administration of Universidade Federal do Parana and has a specialization in Group Dynamics and People Management.
Emmanuelle Camus will assume the role of President of Cognite EMEA. She will focus on accelerating Cognite’s growth and strengthening the company’s position as a leading industrial software provider in the EMEA region in the Energy, Power, and Clean Tech and Manufacturing markets. Prior to joining Cognite, Camus spent 25 years at PTC in various leadership roles focused on business transformation and served most recently as their Senior Vice President of Alliances EMEAI. She has extensive experience in driving exponential growth in Europe & India through B2B sales and leveraging strategic alliances & partners and a strong background in solving Industry 4.0 challenges, digital transformation, Corporate Social Responsibility and Diversity, Equality & Inclusion. She is a graduate of NEOMA Business School.
Paul Lightfoot will support Tanabian as the new Senior Vice President of User Experience as Cognite doubles down on product design to allow customers to exponentially grow the number of data-literate industrial subject matter experts within their organizations. In his role, Lightfoot will lead Cognite's product design vision and strategy to meet these evolving needs as the OT industry is now being software-defined and is evolving into the fusing of physical and digital worlds at scale. Previously, he held product design leadership roles at several high-growth technology companies, most recently building out the product design/user experience practice at Red Hat as its Global Director, User Experience Product Design Team. Paul brings his passion for nurturing and developing a customer-obsessed culture to the role, as well as product management leadership and a focus on the discovery and development of product-market-fit. Paul has a degree in Management Information Systems from Bridgewater State University.
About Cognite
Cognite is a global industrial SaaS company that was established with a clear vision: to rapidly empower industrial companies with contextualized, trustworthy, and accessible data to help drive the full-scale digital transformation of asset-heavy industries around the world. Our core Industrial DataOps platform, Cognite Data Fusion®, enables industrial data and domain users to collaborate quickly and safely to develop, operationalize, and scale industrial AI solutions and applications to deliver both profitability and sustainability. Visit us at www.cognite.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230109005470/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
